Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: Results from a double-blind, randomized, placebo-controlled trial

Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: A phase IIb, randomized, controlled trial

(2012) Wim Van Paesschen et al.   EPILEPSIA

Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: Relationship to anti-convulsant properties

(2011) Michel Gillard et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Adjunctive brivaracetam for refractory partial-onset seizures: A randomized, controlled trial

(2010) J. A. French et al.   NEUROLOGY

Placebo responses in randomized trials of antiepileptic drugs

(2009) A.B. Guekht et al.   EPILEPSY & BEHAVIOR

The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men

(2008) Paul Rolan et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A

(2008) A Matagne et al.   BRITISH JOURNAL OF PHARMACOLOGY

Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy

(2008) Erwin A. van Vliet et al.   EPILEPSIA

SV2A protein is a broad-spectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy

(2007) Rafal M. Kaminski et al.   NEUROPHARMACOLOGY